Come and meet Carol & Rick, limb loss patients now benefitting from Integrum’s bone anchored implant system, at AAOS 2019
Carol Davis and Rick Cicero have both suffered traumatic limb loss experiences. Their quality of life has subsequently benefitted from Integrum’s pioneering OPRA™ bone anchored implant system.
Come and meet Carol and Rick, together with Integrum’s osseointegration and bone anchored prosthetics experts, including Prof. Rickard Brånemark, at Integrum’s booth (#453) at AAOS 2019.
Learn how Integrum and the OPRA™ system are improving quality of life for amputees through higher prosthetic functionality, improved comfort and improved mobility compared to traditionally used socket prostheses.
American Academy of Orthopaedic Surgeons annual meeting (AAOS 2019)
Las Vegas, Nevada, USA
Integrum’s OPRA™ implant system is the only FDA-approved, bone anchored prosthetic solution available in the United States. Based on and refined over almost three decades of osseointegration experience and clinical research, the OPRA™ system enables prosthetics to be directly attached to the bone, thus avoiding the use of socket.
To book a meeting with or for more information about Integrum
Please contact Rutger Barrdahl, CEO, on firstname.lastname@example.org
For more information about Integrum and the OPRA system
Please visit www.integrum.se
For more information about AAOS 2019
Please visit https://www.aaos.org/annual/
We look forward to seeing you there!
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden with a U.S. subsidiary in San Francisco, CA. Since 1990 osseointegration, the science behind the OPRA™ Implant System, has been helping individuals with amputations towards an improved quality of life. Thorough surgical experience gained over almost three decades from 500 surgeries in 13 countries has led to the development of Integrum’s system for bone-anchored prosthetics – a beneficial alternative to the traditionally used socket prosthesis. Integrum’s OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2015 for use in the U.S. under a Humanitarian Use Device (HUD) designation which was reviewed through the Humanitarian Device Exemption (HDE) pathway. The OPRA™ Implant System is the only FDA approved technology for bone anchored prosthetics available in the U.S. More information on the company and its innovative solutions for amputees can be found at www.integrum.se.